Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
08:00am, Friday, 08'th Nov 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade
10:56am, Tuesday, 05'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 96.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, th
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Tuesday, 05'th Nov 2024
Delcath Systems (DCTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed throug
Delcath Systems to Participate in Upcoming Investor Conferences
04:01pm, Friday, 01'st Nov 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Friday, 01'st Nov 2024
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Delcath Systems to Host Third Quarter 2024 Earnings Call
08:30am, Friday, 25'th Oct 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
08:30am, Thursday, 17'th Oct 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 20'th Sep 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
10:21am, Monday, 02'nd Sep 2024
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
04:01pm, Wednesday, 28'th Aug 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
04:01pm, Wednesday, 28'th Aug 2024
NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t
Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +
03:30pm, Friday, 23'rd Aug 2024
In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted
Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits
10:03pm, Sunday, 18'th Aug 2024
Delcath's HEPZATO KIT launch is gaining momentum, setting the company up for a strong 2025. My 2025 sales target is about double the consensus. The stock corrected after the Q2 report due to slower-th
Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript
01:54am, Tuesday, 06'th Aug 2024
Delcath Systems Inc (NASDAQ:DCTH ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerar
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
06:10pm, Monday, 05'th Aug 2024
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.58 per share a year ago.
